What do systematic reviews say?

Donepezil vs placebo

• Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Very low

Donepezil 10 mg/day vs placebo

Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.95 [1.2, 3.15]
  2 studies · 813 participants
  High

Donepezil 10 mg/day vs placebo

Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.15 [0.81, 1.64]
  2 studies · 813 participants
  Moderate

Donepezil 5 mg vs placebo

Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 0.94 [0.72, 1.22]
  3 studies · 1772 participants
  Moderate

Donepezil 5 mg vs placebo

Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.22 [0.94, 1.58]
  3 studies · 1772 participants
  Moderate